FeesSafety
Pluang+

Elauwit reports 66% growth in monthly recurring revenue to $539K, cutting expenses and expanding managed Wi-Fi networks.

Company Fundamentals
19 Nov 2026, 07:27 WIB
The Motley Fool Team
View Source
Bullish
Elauwit reports 66% growth in monthly recurring revenue to $539K, cutting expenses and expanding managed Wi-Fi networks.

Elauwit announced a 66% year-over-year increase in monthly recurring revenue to $539,000 by the end of Q3 2026, driven by long-term contracts for managed Wi-Fi in apartment communities. The company also reduced operating expenses by 19% sequentially to $2.9 million and expanded its billed units by 140% to 25,746. This growth is supported by a bulk managed service model that boosts property owners' net operating income and regional market density that lowers service costs. Elauwit is capitalizing on rapid adoption of managed Wi-Fi by real estate investment trusts, aiming to build local market density and secure long-term recurring revenue.

Elauwit’s recent business growth provides context for readers following real estate investments. For readers following the Real Estate sector, here is Pluang's market snapshot as of Nov 19, 2026 07:11 WIB: Among 47 priced US Real Estate stocks tradable on Pluang, 17 rose and 30 fell today. Notable movers include ARR at USD 10.64 with a 1-day change of -2.83% and Pluang order activity showing 5% Sell / 95% Buy, ARE at USD 42.38 down 2.64%, and CTRE at USD 37.94 up 2.18%. Typical hold times on Pluang range from 35 to 136 days for these stocks.

More News

Micron's strong growth and rising stock price hint at a possible future stock split.

Micron's strong growth and rising stock price hint at a possible future stock split.

Micron Technology is showing strong financial growth, driven by its crucial role in AI infrastructure and multiyear deals with key tech companies. The company recently beat revenue expectations with a 379% year-over-year increase and projects even be...

Company Fundamentals
Bullish
30 minutes ago
FDA approves Livsayis™, first siRNA therapy for generalized myasthenia gravis, offering new treatment option.

FDA approves Livsayis™, first siRNA therapy for generalized myasthenia gravis, offering new treatment option.

The FDA has approved Livsayis™ (cemdisiran), the first and only siRNA therapy for adults with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor antibody-positive. This subcutaneous treatment, administered four times a year, targ...

Market News
Bullish
39 minutes ago
Montauk Renewables delays capital spending, seeks credit amendments amid operational challenges.

Montauk Renewables delays capital spending, seeks credit amendments amid operational challenges.

Montauk Renewables deferred up to $120 million in capital spending and is negotiating credit facility amendments due to operational delays at its North Carolina swine waste project. These delays have created short-term risks for debt covenants, requi...

Company Fundamentals
Neutral
46 minutes ago
Palantir's revenue soars past $2B, outpacing UiPath's slower, seasonal growth in AI software sales.

Palantir's revenue soars past $2B, outpacing UiPath's slower, seasonal growth in AI software sales.

Palantir Technologies has shown rapid quarter-over-quarter revenue growth, reaching $2.3 billion in Q3 2026, driven by strong commercial adoption of its AI platform and expansion beyond government contracts. In contrast, UiPath's revenue growth is mo...

Market News
Bullish
48 minutes ago
Anthropic's IPO may see high demand and price growth despite lower AI investment interest.

Anthropic's IPO may see high demand and price growth despite lower AI investment interest.

Anthropic is launching its IPO with an initial price of $83, but shares may trade higher on the open market due to strong demand. Although AI investment interest has cooled, Anthropic's rapid revenue growth—12 times year-over-year to $17 billion in Q...

Market News
Bullish
51 minutes ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App